Lupin Pharmaceuticals Inc. is recalling 4,179 boxes of Tydemy (drospirenone, ethinyl estradiol and levomefolate calcium tablets). The medication is being recalled because it failed stability testing and was found to contain levels of an impurity that did not meet quality specifications. No injuries or incidents have been reported in connection with this recall.
The tablets were found to have levels of an impurity and a degradation of an inactive ingredient that do not meet standard requirements. This failure to meet specifications could potentially affect the effectiveness of the birth control medication.
You have 2 options:
Distributed by Lupin Pharmaceuticals, Inc., Baltimore, Maryland.
“Tydemy, Rx only, 3 Blisters of 28 Tablets Each”
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · FDA Press Release (1) · FDA Press Release (2) · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.